10-K/A: INVO Bioscience Files Amended 10-K Report, Addresses Executive Compensation and Merger Details

INVO Bioscience has filed an amendment to its annual report on Form 10-K, primarily to include information required by Part III of the form and updated certifications, while also detailing executive compensation, board composition, and the proposed merger with NAYA Biosciences.

Summary

• INVO Bioscience filed an amendment to its annual report on Form 10-K to include information typically found in a proxy statement, as the definitive proxy statement will be filed more than 120 days after the fiscal year end.
• The amendment includes updated certifications from the CEO and CFO, but does not contain financial statements.
• The document details the company's directors and executive officers, including their roles, ages, and professional backgrounds.
• Executive compensation for 2022 and 2023 is provided, including salary, bonuses, stock awards, and option awards.
• The report outlines employment agreements for key executives, including severance terms and potential payments upon termination.
• The document includes a pay versus performance analysis, comparing executive compensation to company performance metrics.
• Director compensation is also detailed, including fees, stock awards, and option awards.
• The report provides information on the company's equity compensation plans, including the number of securities available for issuance.
• Beneficial ownership of the company's common stock is disclosed for major shareholders, directors, and executive officers.
• The document discusses the proposed merger with NAYA Biosciences, including the terms of the merger, the new board composition, and the conditions for closing.
• The company has a related party transaction policy and discloses transactions with related parties, including loans from entities associated with the CFO and CEO.
• The report also includes information on the fees paid to the company's independent accounting firm.
• The document includes an insider trading policy, outlining restrictions on trading company stock based on non-public information.

Sentiment

Score: 4

Explanation: The document contains both positive and negative elements. The proposed merger and corporate governance structure are positive, but the deferred executive salaries, related party transactions, and potential merger termination fee are concerning. The overall sentiment is cautiously negative due to the financial challenges and the uncertainty surrounding the merger.

Positives

• The company has a clear corporate governance structure with independent directors and various committees.
• The company has an insider trading policy in place to prevent illegal trading.
• The company is taking steps to address past due payables.
• The company is actively pursuing a merger with NAYA Biosciences, which could bring new leadership and capital.

Negatives

• The company has significant deferred salary obligations to its executives.
• The company has related party transactions, including loans from entities associated with the CFO and CEO.
• The company has a history of amending its filings, which may raise concerns about internal controls.
• The company has a potential termination fee of $1,000,000 associated with the NAYA merger, which could be a liability if the deal falls through.
• The company has a history of deferring payments to directors and executives.

Risks

• The proposed merger with NAYA Biosciences is subject to several conditions, including financing and shareholder approval, and may not be completed.
• The company's financial condition may be impacted by the need to catch up on past due payables.
• The company's reliance on related party loans could pose a risk if those relationships change.
• The company's stock price could be volatile due to the merger and other factors.
• The company's ability to raise capital may be limited by its current financial situation.

Future Outlook

The company is focused on completing the merger with NAYA Biosciences, which is expected to bring new leadership and capital. The company is also working to address its past due payables and improve its financial position.

Management Comments

• The CEO and CFO have certified that the report does not contain any untrue statements or omissions of material facts.
• The company's board has determined that four of its five directors are independent under Nasdaq listing rules.

Industry Context

The document reflects the typical reporting requirements for a publicly traded company, including detailed information on executive compensation, corporate governance, and related party transactions. The proposed merger with NAYA Biosciences is a significant event that could reshape the company's future. The company operates in the biotechnology sector, which is known for its high-risk, high-reward nature.

Comparison to Industry Standards

• The executive compensation structure, including base salary, stock options, and bonuses, is generally consistent with industry standards for small-cap public companies.
• The board composition, with a majority of independent directors, aligns with best practices in corporate governance.
• The related party transactions, while disclosed, are a potential area of concern and are not uncommon in smaller public companies.
• The company's audit fees are within the range of what is expected for a company of its size and complexity.
• The insider trading policy is a standard practice for public companies to ensure compliance with securities laws.
• The merger agreement with NAYA Biosciences is a complex transaction with several conditions, which is typical for such deals.

Management Changes

Related Party Transactions

• The company issued demand promissory notes to JAG Multi Investments LLC, a company in which the CFO is a beneficiary.
• The company issued demand promissory notes to its CEO and an entity controlled by its CFO.
• The company owes accounts payable to related parties totaling $228,907 as of December 31, 2023.

Stakeholder Impact

• Shareholders will be impacted by the proposed merger with NAYA Biosciences, which could result in a change in control and dilution of existing shares.
• Employees may be impacted by the merger, including potential changes in leadership and operations.
• Creditors may be impacted by the company's efforts to address past due payables.
• Customers and suppliers may be impacted by the merger and any resulting changes in the company's business strategy.

Next Steps

• The company needs to complete the private sale of preferred stock to meet the conditions of the merger agreement.
• The company needs to obtain shareholder approval for the merger with NAYA Biosciences.
• The company needs to file a definitive proxy statement/prospectus with the SEC.
• The company needs to continue to work towards completing the merger with NAYA Biosciences by the extended deadline of April 30, 2024.

Key Dates

Keywords

Merger, Executive Compensation, Corporate Governance, Insider Trading, Related Party Transactions, Stock Options, Board of Directors, Financial Reporting, Audit Fees, INVO Bioscience, NAYA Biosciences